The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
What about someone that has, genetic risk factors? Let's say they have a genetic risk factor like, you know, they would have an ApoE4 allele, which means they can't recycle the LDL cholesterol back to the liver as efficiently.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So the ApoE4 axis sort of amplifies the risk associated with small LDL or any other lipid, or heart disease risk factor. But the recommendations for trying to monitor or manage small LDL particles, I thought about this a lot recently, I think they represent sort of a separate axis from the ApoE. I think the ApoE axis amplifies the risk, but it doesn't necessarily change the fundamental biology for the production of the small LDL particles.